329 related articles for article (PubMed ID: 36977797)
1. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
Rose KM; Huelster HL; Meeks JJ; Faltas BM; Sonpavde GP; Lerner SP; Ross JS; Spiess PE; Grass GD; Jain RK; Kamat AM; Vosoughi A; Wang L; Wang X; Li R
Nat Rev Urol; 2023 Jul; 20(7):406-419. PubMed ID: 36977797
[TBL] [Abstract][Full Text] [Related]
2. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature.
Green EA; Li R; Albiges L; Choueiri TK; Freedman M; Pal S; Dyrskjøt L; Kamat AM
Eur Urol Oncol; 2021 Dec; 4(6):893-903. PubMed ID: 33975782
[TBL] [Abstract][Full Text] [Related]
4. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P; Hoimes CJ; Gopalakrishnan D; Barata PC; Drakaki A; Faltas BM; Kiedrowski LA; Lanman RB; Nagy RJ; Vogelzang NJ; Boucher KM; Vaishampayan UN; Sonpavde G; Grivas P
Cancer; 2018 May; 124(10):2115-2124. PubMed ID: 29517810
[TBL] [Abstract][Full Text] [Related]
5. [High-throughput molecular analysis of urothelial carcinoma: potential clinical applications].
Todenhöfer T; Miernik A; Seiler R
Aktuelle Urol; 2019 Feb; 50(1):84-93. PubMed ID: 30731506
[TBL] [Abstract][Full Text] [Related]
6. Genomics in upper tract urothelial carcinoma.
Kammerer-Jacquet SF; Mathieu R; Peyronnet B; Rioux-Leclercq N; Bensalah K
Curr Opin Urol; 2017 Jan; 27(1):35-40. PubMed ID: 27584028
[TBL] [Abstract][Full Text] [Related]
7. Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC.
Mu N; Jylhä C; Axelsson T; Sydén F; Brehmer M; Tham E
World J Urol; 2023 Dec; 41(12):3421-3427. PubMed ID: 37721600
[TBL] [Abstract][Full Text] [Related]
8. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M
Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110
[TBL] [Abstract][Full Text] [Related]
9. Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma.
Tamura D; Abe M; Hiraki H; Sasaki N; Yashima-Abo A; Ikarashi D; Kato R; Kato Y; Maekawa S; Kanehira M; Takata R; Maejima K; Sasagawa S; Fujita M; Suzuki Y; Nakagawa H; Iwaya T; Nishizuka SS; Obara W
Cancer Sci; 2024 Feb; 115(2):529-539. PubMed ID: 38083992
[TBL] [Abstract][Full Text] [Related]
10. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
11. Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report.
Blumendeller C; Boehme J; Frick M; Schulze M; Rinckleb A; Kyzirakos C; Kayser S; Kopp M; Kelkenberg S; Pieper N; Bartsch O; Hadaschick D; Battke F; Stenzl A; Biskup S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33431630
[TBL] [Abstract][Full Text] [Related]
12. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
Shohdy KS; Villamar DM; Cao Y; Trieu J; Price KS; Nagy R; Tagawa ST; Molina AM; Sternberg CN; Nanus DM; Mosquera JM; Elemento O; Sonpavde GP; Grivas P; Vogelzang NJ; Faltas BM
Br J Cancer; 2022 Feb; 126(3):430-439. PubMed ID: 35046520
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of Chinese patients with urothelial carcinoma.
Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S
BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsy in urothelial carcinoma: Detection techniques and clinical applications.
Wu S; Li R; Jiang Y; Yu J; Zheng J; Li Z; Li M; Xin K; Wang Y; Xu Z; Li S; Chen X
Biomed Pharmacother; 2023 Sep; 165():115027. PubMed ID: 37354812
[TBL] [Abstract][Full Text] [Related]
15. The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder.
Rink M; Schwarzenbach H; Riethdorf S; Soave A
World J Urol; 2019 Sep; 37(9):1785-1799. PubMed ID: 30367205
[TBL] [Abstract][Full Text] [Related]
16. Molecular Pathology of Urothelial Carcinoma.
Al-Ahmadie H; Netto GJ
Clin Lab Med; 2024 Jun; 44(2):181-198. PubMed ID: 38821640
[TBL] [Abstract][Full Text] [Related]
17. Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial.
Zang J; Zhang R; Jin D; Xie F; Shahatiaili A; Wu G; Zhang Y; Zhao Z; Du P; Jia S; Chen H; Zhuang G
J Pathol; 2023 Oct; 261(2):198-209. PubMed ID: 37584165
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsies for detection, surveillance, and prognosis of urothelial cancer: a future standard?
Duquesne I; Abou Chakra M; Hage L; Pinar U; Loriot Y
Expert Rev Anticancer Ther; 2023; 23(9):995-1007. PubMed ID: 37542214
[TBL] [Abstract][Full Text] [Related]
19. Detection of Copy Number Imbalance in Canine Urothelial Carcinoma With Droplet Digital Polymerase Chain Reaction.
Mochizuki H; Shapiro SG; Breen M
Vet Pathol; 2016 Jul; 53(4):764-72. PubMed ID: 26574558
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer.
Chalfin HJ; Glavaris SA; Gorin MA; Kates MR; Fong MH; Dong L; Matoso A; Bivalacqua TJ; Johnson MH; Pienta KJ; Hahn NM; McConkey DJ
Eur Urol Oncol; 2021 Apr; 4(2):310-314. PubMed ID: 31563523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]